Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Bayer1,001 enrolled

Overview

This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.

Study Type

OBSERVATIONAL

Enrollment

1,001

Conditions

Secondary Peritonitis Abscess, Intra-Abdominal

Interventions

Moxifloxacin (Avelox, BAY12-8039)DRUG

The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients at least 18 years of age with a diagnosis of cIAI treated with Moxifloxacin infusion with/without sequential tablet treatment can be included into the study. The local Moxifloxacin product information must be considered. Exclusion Criteria: * Contraindications stated in the local Moxifloxacin product information. Warnings and precautions, stated in the local Moxifloxacin product information must be considered as potential exclusion criteria.

Locations (1)

Unnamed facility

Many Locations, China

Outcomes

Primary Outcomes

Types of cIAI infections

Time frame: Day 1

Secondary Outcomes

Cure rate

Time frame: 5-14 days

Clinical signs and symptoms

Time frame: 5-14 days

Duration until improvement and cure

Time frame: 5-14 days

Adverse event collection

Time frame: 5-14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.